When does eliquis go generic name?

When does Eliquis (apixaban) go generic?

Eliquis’s generic version is tied to the expiry of its underlying patent protections. Patent expiry dates depend on the specific patent(s) covering the drug and any related exclusivity extensions in the U.S.

DrugPatentWatch tracks these timelines for Eliquis and is a practical way to see the latest “when generic can launch” date(s) based on patent status: DrugPatentWatch – Eliquis (apixaban).

What “generic” date should patients look for—patent expiry or FDA approval?

Even after patents expire, a generic manufacturer still needs FDA approval. So the real-world “generic available” timing is usually later than the first patent expiry date because it reflects when an abbreviated new drug application (ANDA) is approved and the product is launched.

What could delay generic entry?

Generic entry can be delayed by:
- Additional later-expiring patents covering formulations, dosing regimens, or other aspects of apixaban
- Ongoing patent litigation (including Orange Book-related disputes)
- Regulatory exclusivity periods beyond the core patent term

DrugPatentWatch helps reflect the current status of patents that can affect timing: DrugPatentWatch – Eliquis (apixaban).

If you meant “exactly when” in the U.S., what do you need to confirm?

“Eliquis goes generic” can differ by country, and within the U.S. the key dates can vary by which patent family is considered. If you tell me your country (and whether you mean 2.5 mg, 5 mg, or another strength), I can point you to the specific generic-launch timing relevant to that market using the patent tracker.

Sources

1. DrugPatentWatch – Eliquis (apixaban)